AHA Abstract 13266: Non-contrast 3D Magnetic Resonance Imaging Offers and Alternative to Contrast Enhanced Multisclice Computed Tomography for Correct Aortic Valve Sizing in Patients Undergoing Transcatheter Aortic Valve Implantation

  • Imaging
    • Session Title: Magnetic Resonance Imaging (MRI): Transplants / Congenital Heart Disease / Structural Heart Disease

Abstract 13266: Non-contrast 3D Magnetic Resonance Imaging Offers and Alternative to Contrast Enhanced Multisclice Computed Tomography for Correct Aortic Valve Sizing in Patients Undergoing Transcatheter Aortic Valve Implantation

  1. Peter Bernhardt;
  2. Christoph Rodewald;
  3. Julia Seeger;
  4. Birgid Gonska;
  5. Dominik Buckert;
  6. Wolfgang Rottbauer;
  7. Jochen Wöhrle

Author Affiliations


  1. Internal Medicine II, Univ of Ulm, Ulm, Germany
Advertisements

Scientific Meeting of the Japanese Circulation Society

81st Annual Scientific Meeting of the Japanese Circulation Society (JCS2017) which will be held at Kanazawa in March 17-19, 2017

Clinical performance of a novel ultrathin strut, low-dose, sirolimus-eluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention in the daily practice.

pubmed link

Cardiovasc Diagn Ther. 2015 Dec;5(6):414-419.

Clinical performance of a novel ultrathin strut, low-dose, sirolimus-eluting stent with abluminal-only biodegradable polymeric coating for patients undergoing percutaneous coronary intervention in the daily practice.

Abstract

BACKGROUND:

The present study aimed to evaluate the clinical performance, in the daily practice of a busy catheterization laboratory, of a novel drug-eluting stent (DES) built with an ultra-thin-strut metallic platform, eluting sirolimus at low doses, abluminal coated with biodegradable polymers, and mounted in a low-compliant delivery system.

METHODS:

Prospective, single-arm study, comprising all consecutive patients undergoing percutaneous coronary intervention (PCI) with the Inspiron™ sirolimus-eluting stent (SES) (Scitech, Aparecida de Goiania, Brazil). The primary endpoint was the occurrence of major adverse cardiac events (MACE) [cardiac death, non-PCI related myocardial infarction (MI), or target vessel revascularization (TVR)].

RESULTS:

A total of 470 patients were included, from which 51.3% were diabetics, 33.8% had triple-vessel disease, 15.3% had heart failure, 38.9% had at least one bifurcation treated, 19.8% were treated for a bare metal stent restenosis, and 61.9% had at least one type C lesion; one or more of these features were found in 96.0%. At 300 days, the rate target lesion revascularization was 5.4% and the rate of MACE was 8.1%. The incidence of definite or probable stent thrombosis was 0.4%, with no cases between 30 and 300 days.

CONCLUSIONS:

The novel stent is associated with excellent short and mid-term clinical outcomes in patients treated with PCI in the daily practice.

lemos stent 7225-PB4-R1

RSNA 2015